Preliminary results for the year ended 31 December 2016
3 March 2017
Commenting on performance for the year, Xavier Rolet, Chief Executive said:
“The Group continues to execute against its strategic objectives, driving both short and longer term growth through organic investment and selective inorganic opportunities. This has resulted in another year of strong financial performance, with continued revenue growth, control of underlying expenses and a 21% increase in adjusted earnings per share. Each of our business areas delivered year-on-year growth, highlighting the strength in the diversity of our business, launching new products such as LCH Spider, new services in partnership with customers such as CurveGlobal and Turquoise Plato, and expanding our global footprint with acquisitions such as Mergent Inc.
“FTSE Russell produced another good top line performance and the integration savings are now mostly achieved, ahead of schedule. The LCH OTC clearing services performed well, particularly SwapClear and its compression services. We remain well positioned across all our businesses, underpinned by our Open Access approach and strong customer partnerships.”